I now have thorough content from Campbell-Walsh Urology and Smith & Tanagho. Let me compile a comprehensive answer.
Urinary Urgency
Definition
Urinary urgency is defined by the International Continence Society (ICS) as "a sudden compelling desire to pass urine, which is difficult to defer." While some degree of urge to void is normal when the bladder has been held for a prolonged time, pathological urgency should not occur under ordinary circumstances.
- Campbell-Walsh Wein Urology: "Urinary urgency indicates difficulty in postponing urination... it should not occur otherwise."
- Smith & Tanagho's General Urology (19th ed.): Urgency is a lower urinary tract storage symptom distinct from the normal physiological sensation of bladder fullness ("urge").
Overactive Bladder (OAB) - The Core Syndrome
Urgency is the hallmark symptom of Overactive Bladder (OAB):
OAB = Urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence (UUI), in the absence of UTI or other obvious pathology.
- OAB "wet" - urgency + urge incontinence (involuntary urine loss associated with urgency)
- OAB "dry" - urgency without incontinence
Pathophysiology
Urgency/OAB can arise from dysfunction at three levels:
| Origin | Mechanism |
|---|
| Neurogenic | Brain/spinal cord lesions removing inhibitory control (e.g., stroke, MS, Parkinson's, spinal cord injury above sacrum) |
| Myogenic | Detrusor smooth muscle instability or low bladder compliance |
| Urothelial | Abnormal afferent signaling from urothelium (e.g., interstitial cystitis, inflammation) |
Common underlying causes include: neuropathic injury, bladder outlet obstruction (BPH), UTI/cystitis, bladder stones, diabetes mellitus, interstitial cystitis, and radiation cystitis.
The basic urodynamic finding is detrusor overactivity (DO) - involuntary detrusor contractions during filling. Note: up to 50% of OAB patients may not show DO on urodynamics on any given study, so clinical context matters.
Differential Diagnosis of Urgency
| Cause | Key Features |
|---|
| OAB (idiopathic) | Frequency, nocturia, no infection |
| UTI/cystitis | Dysuria, pyuria, bacteriuria |
| Bladder stones | Hematuria, pain |
| Bladder cancer | Hematuria, especially in >50 yr smokers |
| Interstitial cystitis/BPS | Severe pelvic/bladder pain, frequency, no infection |
| BPH (men) | Obstructive + irritative LUTS, weak stream |
| Neurogenic bladder | Neurological history, examination signs |
| Radiation cystitis | History of pelvic radiation |
Important: In patients >50 years with a smoking history, irritative voiding symptoms (urgency, frequency, dysuria) can be the only presenting sign of bladder cancer - this mandates urological evaluation.
Evaluation
- History - onset, frequency, nocturia, incontinence, hematuria, neurological symptoms, pelvic surgery/radiation, medications
- Bladder diary (48 hours) - volumes voided, fluid intake, urgency episodes, incontinence - reveals functional capacity (~300-400 mL normal adult), polyuria, nocturia patterns
- Urinalysis + urine culture - exclude UTI, hematuria
- Post-void residual (PVR) - exclude incomplete emptying
- Urodynamics (UDS) - reserved for: diagnosis in doubt, failed initial therapy, suspected neurogenic bladder, coexisting BOO, significant PVR, or pre-surgical workup
- Cystoscopy - if hematuria, refractory symptoms, or suspected malignancy
Treatment - Stepwise Approach
Step 1: Conservative / Behavioral (6-12 weeks minimum)
- Fluid management - reduce intake by ~25% if drinking >1 L/day; avoid caffeine, alcohol, carbonated drinks
- Bladder training - gradually increase voiding intervals; teaches suppression of urgency
- Pelvic floor muscle training (PFMT) - urgency suppression with voluntary pelvic floor contraction
- Bowel management (constipation worsens OAB)
- Weight loss, smoking cessation
Step 2: Pharmacotherapy
Antimuscarinics (9 agents with Grade A evidence, Level 1):
| Drug | Notes |
|---|
| Oxybutynin | Available oral, patch, topical gel; most side effects |
| Tolterodine | Widely used; extended-release preferred |
| Solifenacin | Better efficacy than tolterodine; less dry mouth |
| Fesoterodine | Better efficacy vs. tolterodine; higher discontinuation |
| Darifenacin | M3-selective; less CNS effects |
| Trospium chloride | Quaternary amine; minimal BBB crossing; less cognitive effect |
| Propiverine | Available in some countries |
- Extended-release formulations preferred over immediate-release for tolerability
- Main side effects: dry mouth, constipation, blurred vision, cognitive effects (especially in elderly)
Beta-3 agonist:
- Mirabegron - relaxes detrusor via β₃ receptors; proven superiority to tolterodine for incontinence episodes and frequency; less dry mouth/constipation than antimuscarinics; side effects include palpitations and hypertension
- Combination therapy (mirabegron 50 mg + solifenacin 5 mg) is superior to dose escalation of solifenacin alone, with better efficacy and fewer side effects (Drake et al., 2016)
Step 3: Minimally Invasive Procedures
- OnabotulinumtoxinA (Botox) intravesical injection - reduces detrusor overactivity; effective for refractory OAB and neurogenic detrusor overactivity; risk of urinary retention (patient should be able to self-catheterize)
- Sacral nerve modulation (SNM/InterStim) - implanted neuromodulation; used for refractory OAB and UUI
- Posterior tibial nerve stimulation (PTNS) - percutaneous or transcutaneous; less invasive neuromodulation option
Step 4: Surgical (rarely needed)
- Bladder augmentation cystoplasty - increases capacity; significant morbidity; for severe refractory cases
- Urinary diversion (e.g., ileal conduit) - last resort
Special Populations
- Neurogenic bladder - urgency with DO is the most common pattern in lesions above the brainstem or above the sacral cord; DESD (detrusor-external sphincter dyssynergia) may coexist in suprasacral lesions; antimuscarinics used; Botox has strong evidence
- Elderly - antimuscarinics carry cognitive risk; prefer trospium, darifenacin, or mirabegron; assess fall risk
- Women - estrogen deficiency contributes to urgency; topical vaginal estrogen may help (not systemic)
- BPH (men) - combination alpha-blocker + antimuscarinic or mirabegron for mixed LUTS
Key Points
- Urgency = sudden compelling desire to void, difficult to defer
- OAB = urgency ± frequency, nocturia, ± incontinence; no infection
- Always rule out UTI, hematuria, neurological cause
- First-line: behavioral therapy (bladder training, PFMT, fluid management)
- Second-line: antimuscarinics or mirabegron (Grade A evidence)
- Refractory: Botox injection or sacral neuromodulation
- Hematuria + urgency in a smoker >50 years = cystoscopy mandatory
Sources: Campbell-Walsh Wein Urology (10th ed.); Smith & Tanagho's General Urology (19th ed.); Bradley & Daroff's Neurology in Clinical Practice